SmithKline NicoDerm CQ "only" three-step system claims to be modified, NAD reports.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE NICODERM CQ UNIQUENESS CLAIMS TO BE MODIFIED in response to a complaint filed with the National Advertising Division of the Council of Better Business Bureaus by Novartis, which markets the Rx nicotine smoking cessation patch Habitrol. In a Jan. 13 NAD Case Report, the advertising review group details how SmithKline Beecham has agreed to modify claims appearing in a "Commit to Quit" newspaper ad and promotional pamphlet that portray NicoDerm CQ as "the only patch that gradually reduces your nicotine dose in three simple steps" and the "only patch that can be used by light and heavy smokers."